Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study

Journal of Clinical Oncology

Volumn 18, Issue 17, 2000, Pages 3068-3077

  Von der Maase, H ^a   Hansen, S W ^a   Roberts, J T ^a   Dogliotti, L ^a   Oliver, T ^a   Moore, M J ^a   Bodrogi, I ^a   Albers, P ^a   Knuth, A ^a   Lippert, C M ^a   Kerbrat, P ^a   Sanchez Rovira, P ^a   Wersall, P ^a   Cleall, S P ^a   Roychowdhury, D F ^a   Tomlin, I ^a   Visseren Grul, C M ^a   Conte, P F ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; FOLINIC ACID; GEMCITABINE; METHOTREXATE;

ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ARTICLE; BLADDER CANCER; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORTALITY; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEPSIS; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT FAILURE; TREATMENT OUTCOME; UROTHELIUM;

EID: 0033857218     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.17.3068     Document Type: Article

References (20)

1. Global cancer statistics
2. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium
3. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study
4. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors
5. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelial: Efficacy and patterns of response and relapse
6. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study
7. Weekly gemcitabine in advanced bladder cancer: A preliminary report from a phase I study
8. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer
9. Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer
10. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum: Italian Cooperative Group on Bladder Cancer
11. Interaction between cisplatin and gemcitabine in vitro and in vivo
12. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: A phase II clinical trial
13. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada Clinical Trials Group
14. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer
15. Gemcitabine in locally and/or metastatic bladder cancer
16. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial
17. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy
18. A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer
19. Evaluation of drug delivery and survival impact of dose-intense relative to conventional-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in urothelial cancer
20. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer